Curis, Inc. (CRIS)
Oxford Ledge is still expanding full research coverage of CRIS. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A biotechnology company developing emavusertib for blood cancers through multiple clinical trials while managing substantial funding constraints.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K 3.03; Amendments to articles or bylaws; Financial statements and exhibits 2026-07-02
- 8-K Amendments to articles or bylaws 2026-07-01
- 8-K Shareholder vote results 2026-06-25
- DEF 14A Proxy statement for shareholder vote 2026-06-05
- 8-K 3.03; Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-05-22
Source: SEC EDGAR.
Annual results
5 years of annual figures for CRIS, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $9.4M | -$7.6M | -$0.58 |
| 2024 | $10.9M | -$43.4M | -$6.88 |
| 2023 | $10.0M | -$47.4M | -$8.96 |
| 2022 | $10.2M | -$56.7M | -$12.14 |
| 2021 | $10.6M | -$45.4M | $0.50 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for CRIS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CRIS in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.